UBS Group AG Buys 88,314 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• UBS Group AG raised its stake in Kymera by 13.6%, buying 88,314 shares to own 737,032 shares (~1.02%) valued at about $57.35 million per its SEC filing.
• Insiders have sold heavily recently—380,734 shares worth roughly $32.19 million in the last 90 days (including CEO Nello Mainolfi’s 30,000‑share sale and Noah Goodman’s 8,264‑share sale)—but corporate insiders still own 16.01% of the company.
• Kymera beat Q1 estimates (EPS -$0.71 vs. -$0.89 forecast; revenue $34.37M vs. $8.27M est., +55.5% YoY) and reported positive preclinical data for KT‑579, helping prompt analyst upgrades and a consensus "Moderate Buy."

UBS Group AG lifted its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 737,032 shares of the company's stock after buying an additional 88,314 shares during the period. UBS Group AG owned approximately 1.02% of Kymera Therapeutics worth $57,348,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Larson Financial Group LLC boosted its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after buying an additional 349 shares during the period. Bessemer Group Inc. boosted its stake in shares of Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after buying an additional 815 shares during the period. Osaic Holdings Inc. lifted its stake in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Kymera Therapeutics during the second quarter worth $73,000. Finally, US Bancorp DE raised its holdings in shares of Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company's stock worth $106,000 after buying an additional 166 shares in the last quarter.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera presented new preclinical data showing KT‑579 (oral IRF5 degrader) produced activity comparable or superior to approved/clinically active therapies in IBD models — a meaningful R&D positive if confirmed in clinical studies. Article Title
• Positive Sentiment: Management will participate in multiple May investor conferences (fireside chats), increasing visibility with investors and analysts — typically supportive for sentiment and liquidity. Article Title
• Positive Sentiment: Q1 results and the accompanying presentation prompted analysts to lift estimates in some reports and coverage; positive analyst reaction to quarterly revenue and beats can support the stock. Article Title
• Neutral Sentiment: Kymera published its Q1 earnings presentation (details on pipeline progress, financials and guidance assumptions), useful for investors but not an immediate catalyst by itself. Article Title
• Neutral Sentiment: Company celebrated its 10‑year anniversary and rang the Nasdaq opening bell — PR/branding event with limited direct impact on valuation. Article Title
• Negative Sentiment: Brookline Capital Markets issued multiple model changes: they raised some near‑ and long‑term estimates (e.g., FY2026, FY2028–FY2030) but lowered Q3/Q4 2026 and FY2027 forecasts — the mixed/downgrade elements could weigh on sentiment by signaling slower expected progress or higher near‑term spend. Article Title

Insider Transactions at Kymera Therapeutics

In other news, insider Noah Goodman sold 8,264 shares of Kymera Therapeutics stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $87.50, for a total value of $723,100.00. Following the completion of the transaction, the insider directly owned 53,542 shares of the company's stock, valued at approximately $4,684,925. This trade represents a 13.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00. Following the completion of the transaction, the chief executive officer directly owned 666,195 shares of the company's stock, valued at approximately $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 380,734 shares of company stock worth $32,193,902. Corporate insiders own 16.01% of the company's stock.

Kymera Therapeutics Stock Down 1.1%

Shares of NASDAQ:KYMR opened at $82.71 on Wednesday. The firm has a market cap of $6.80 billion, a P/E ratio of -23.17 and a beta of 2.06. Kymera Therapeutics, Inc. has a 12-month low of $28.06 and a 12-month high of $103.00. The business has a fifty day simple moving average of $84.42 and a 200 day simple moving average of $76.61.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. The business had revenue of $34.37 million during the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.Kymera Therapeutics's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the company earned ($0.82) EPS. As a group, equities research analysts expect that Kymera Therapeutics, Inc. will post -3.35 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on KYMR shares. Canaccord Genuity Group started coverage on Kymera Therapeutics in a report on Wednesday. They set a "buy" rating and a $106.00 price target for the company. Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. Citigroup boosted their price target on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a report on Monday, March 2nd. Finally, BTIG Research cut their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.